Phenytoin Testing Market Size, Research & Analysis Pr

1
Global Phenytoin Testing Market to be Propelled
by Growing Incidents of Phenytoin Toxicity and
Preventive Care of Kidney and Central Nervous
System (CNS) by CAGR of 2 During 2023
2033 Kenneth Research published a report titled
Phenytoin Testing Market Global Demand
Analysis Opportunity Outlook 2033 which
delivers detailed overview of the global
phenytoin testing market in terms of market
segmentation by product type, end-user and by
region. Further, for the in-depth analysis, the
report encompasses the industry growth
indicators, restraints, supply and demand risk,
along with detailed discussion on current and
future market trends that are associated with the
growth of the market.
The global phenytoin testing market is expected
to hold a revenue of USD 8 billion by 2033,
growing from USD 7 billion in 2022. The market
growth can be attributed to the increase in the
incidents of phenytoin toxicity, the relevance of
the test in the preventive care of kidney and
CNS diseases, cases of epilepsy and post-surgical
seizures, expansion
2
of services by key service providers, demand for
point-of-care testing, and awareness about drug
abuse and drug adherence. The global phenytoin
testing market is expected to grow at a CAGR of
approximately 2 from 2023-2033. The market is
segmented by end-user into hospitals,
pathological laboratories, and research centers.
Of these, the hospitals' segment is anticipated
to hold the largest market share by the end of
2033, owing to the increase in the number of
hospitals worldwide and the considerable
developments in healthcare infrastructure. For
more description_at_https//www.kennethresearch.com/r
eport-details/phenytoin- testing-market/10352433
The global phenytoin testing market is divided
into five major regions, including North
America, Europe, Asia Pacific, Latin America, and
Middle East Africa. The market in North
America is projected to hold the largest market
share by the end of 2033, backed by the rise in
the number of active epilepsy cases and the
growth of pathological labs and health care
infrastructure. The research is global in nature
and covers detailed analysis on the market in
North America (U.S., Canada), Europe (U.K.,
Germany, France, Italy, Spain, Hungary, Belgium,
Netherlands Luxembourg, NORDIC Finland,
Sweden, Norway, Denmark, Poland, Turkey,
Russia, Rest of Europe), Latin America (Brazil,
Mexico, Argentina, Rest of Latin America),
Asia-Pacific (China, India, Japan, South Korea,
Indonesia, Singapore, Malaysia, Australia, New
Zealand, Rest of Asia-Pacific), Middle East and
Africa (Israel, GCC Saudi Arabia, UAE, Bahrain,
Kuwait, Qatar, Oman, North Africa, South Africa,
Rest of Middle East and Africa). In addition,
analysis comprising market size, Y-O-Y growth
opportunity analysis, market players competitive
study, investment opportunities, demand for
future outlook etc. has also been covered and
displayed in the research report. Significance
in the Preventive Care of Kidney and CNS to Boost
the Market Growth
3
According to a report on Uremia by the National
Centre for Biotechnology Information (NCBI),
about 354 people in a million are diagnosed with
end-stage renal disease (ESRD) every year.
Similarly, every year, more than 17 million
people are thought to misuse prescription drugs,
including CNS depressants. Phenytoin toxicity in
patients of epilepsy, especially when the drug
has not been overused, indicates conditions of
renal failure, including hypoalbuminemia and
uremia. Thus, phenytoin testing is beneficial in
the early detection of renal failure. As in the
case of any other CNS depressants, the overuse
of phenytoin puts a patient at risk of mental
and physical issues and can even lead to death.
So, the regular monitoring of phenytoin levels
in the blood can prevent the adverse effect of
phenytoin toxicity on the CNS. However,
inconsistent test results, expenses related to
the regular monitoring of phenytoin levels, and
the availability of alternatives for phenytoin
are expected to operate as key restraint to the
growth of global phenytoin testing market over
the forecast period. This report also provides
the existing competitive scenario of some of the
key players of the global phenytoin testing
market which includes company profiling of
Abbott, ARUP Laboratories, Quest Diagnostics
Incorporated, Lybrate Inc., Portea Medical,
Pfizer Inc., Sun Pharmaceutical Industries Ltd.,
Randox Laboratories Ltd., Personalabs, Roche
Diagnostics, and others. The profiling enfolds
key information of the companies which
encompasses business overview, products and
services, key financials and recent news and
developments. On the whole, the report depicts
detailed overview of the global phenytoin
testing market that will help industry
consultants, equipment manufacturers, existing
players searching for expansion opportunities,
new players searching possibilities and other
stakeholders to align their market centric
strategies according to the ongoing and expected
trends in the future. Request Report Sample_at_
https//www.kennethresearch.com/sample-request-
10352433
4
Kenneth Research is a leading service provider
for strategic market research and consulting. We
aim to provide unbiased, unparalleled market
insights and industry analysis to help
industries, conglomerates and executives to take
wise decisions for their future marketing
strategy, expansion and investment etc. We
believe every business can expand to its new
horizon, provided a right guidance at a right
time is available through strategic minds. Our
out of box thinking helps our clients to take
wise decision in order to avoid future
uncertainties. Contact for more Info AJ
Daniel Email sales_at_kennethresearch.com U.S.
Phone [phone]